Kite Pharma, Inc. Insider Trading for April 2017
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Kite Pharma, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in Kite Pharma, Inc. for April 2017.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 27 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Option Exercise | M | 1.35 | 15,000 | 20,250 | 125,394 | |
| Apr 27 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Sell | S | 82.87 | 3,742 | 310,100 | 117,795 | 121.5 K to 117.8 K (-3.08 %) |
| Apr 27 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Sell | S | 82.14 | 5,545 | 455,466 | 121,537 | 127.1 K to 121.5 K (-4.36 %) |
| Apr 27 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Sell | S | 80.89 | 5,713 | 462,125 | 127,082 | 132.8 K to 127.1 K (-4.30 %) |
| Apr 27 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Buy | M | 1.35 | 15,000 | 20,250 | 132,795 | 117.8 K to 132.8 K (+12.73 %) |
| Apr 26 2017 | KITE | Kite Pharma, Inc. | CHAMPSI FARAH | Director | Sell | S | 83.06 | 200 | 16,612 | 24,130 | 24.3 K to 24.1 K (-0.82 %) |
| Apr 26 2017 | KITE | Kite Pharma, Inc. | CHAMPSI FARAH | Director | Sell | S | 82.72 | 51,112 | 4,227,985 | 24,330 | 75.4 K to 24.3 K (-67.75 %) |
| Apr 26 2017 | KITE | Kite Pharma, Inc. | CHAMPSI FARAH | Director | Sell | S | 83.29 | 15,316 | 1,275,670 | 75,442 | 90.8 K to 75.4 K (-16.88 %) |
| Apr 26 2017 | KITE | Kite Pharma, Inc. | CHAMPSI FARAH | Director | Sell | S | 82.56 | 31,467 | 2,597,916 | 90,758 | 122.2 K to 90.8 K (-25.75 %) |
| Apr 26 2017 | KITE | Kite Pharma, Inc. | CHAMPSI FARAH | Director | Sell | S | 82.34 | 25,818 | 2,125,854 | 122,225 | 148 K to 122.2 K (-17.44 %) |
| Apr 17 2017 | KITE | Kite Pharma, Inc. | CHAMPSI FARAH | Director | Sell | S | 83.06 | 100 | 8,306 | 148,043 | 148.1 K to 148 K (-0.07 %) |
| Apr 17 2017 | KITE | Kite Pharma, Inc. | CHAMPSI FARAH | Director | Sell | S | 82.48 | 43,001 | 3,546,722 | 148,143 | 191.1 K to 148.1 K (-22.50 %) |
| Apr 17 2017 | KITE | Kite Pharma, Inc. | CHAMPSI FARAH | Director | Sell | S | 82.39 | 72,275 | 5,954,737 | 191,144 | 263.4 K to 191.1 K (-27.44 %) |
| Apr 04 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Option Exercise | M | 6.89 | 20,000 | 137,800 | 143,000 | |
| Apr 04 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 83.66 | 700 | 58,562 | 50,165 | 50.9 K to 50.2 K (-1.38 %) |
| Apr 04 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 82.60 | 8,697 | 718,372 | 50,865 | 59.6 K to 50.9 K (-14.60 %) |
| Apr 04 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 82.00 | 3,549 | 291,018 | 59,562 | 63.1 K to 59.6 K (-5.62 %) |
| Apr 04 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 80.44 | 2,424 | 194,987 | 63,111 | 65.5 K to 63.1 K (-3.70 %) |
| Apr 04 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 79.63 | 3,939 | 313,663 | 65,535 | 69.5 K to 65.5 K (-5.67 %) |
| Apr 04 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 78.53 | 691 | 54,264 | 69,474 | 70.2 K to 69.5 K (-0.98 %) |
| Apr 04 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Buy | M | 6.89 | 20,000 | 137,800 | 70,165 | 50.2 K to 70.2 K (+39.87 %) |